Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple
dose study in male and female patients ages 50 to less than 89 years with mild to moderate
AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be
randomized to receive either bapineuzumab or placebo. Each patient's participation will last
approximately 1.5 years.
Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid
peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Phase:
Phase 3
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC